Veteran pharmaceutical company AstraZeneca (AZN +3.23%) delivered for investors on the second-to-last trading day of the week. Its shares rose by more than 3% across that trading session, thanks mostly to an earnings report that featured a pair of convincing beats. The stock's rise came on a generally gloomy day for the market, as the S&P 500 (^GSPC 1.12%) slumped by 1.1%.
Healthy increases
AstraZeneca posted its third-quarter and nine-month figures well before market open that day. These revealed that the company earned nearly $15.2 billion during the former period, a solid 12% higher than in the same quarter of 2024. The company said it saw sales growth in all therapeutic areas, particularly oncology (up 16% year over year) and respiratory and immunology (up 13%).
Image source: Getty Images.
On the bottom line, AstraZeneca's operating profit not according to generally accepted accounting principles (GAAP) rose by 16% to just under $5 billion, or $2.38 per share.
With that performance, AstraZeneca beat the average analyst estimates -- particularly that for non-GAAP (adjusted) profitability. Pundits tracking the company were expecting only $1.22 per share for the metric. Revenue also was a consensus beater, as the collective prognosticator expectation was for under $14.8 billion.
NASDAQ: AZN
Key Data Points
More growth on the way?
AstraZeneca also reaffirmed its existing guidance for full-year 2025. At constant exchange rates, revenue is anticipated to rise at a high-single-digit percentage rate over the 2024 tally.
Adjusted earnings per share should rise at a low double-digit rate. The company did not get more specific.
